Chronic administration of palmitoleic acid reduces insulin resistance and hepatic lipid accumulation in KK-Ay Mice with genetic type 2 diabetes

Zhi-Hong Yang, Hiroko Miyahara, Akimasa Hatanaka, Zhi-Hong Yang, Hiroko Miyahara, Akimasa Hatanaka

Abstract

Background: Studies have demonstrated the beneficial effect of palmitoleic acid (C16:1 n-7) on reducing muscle insulin resistance and preventing beta-cell apoptosis. However, the effect of palmitoleic acid on diabetes remains to be elucidated. The aim of this study was to examine the antidiabetic effect of palmitoleic acid in KK-Ay mice, a spontaneous model for studies of obese type 2 diabetes with low insulin sensitivity.

Methods: KK-Ay mice were orally administered vehicle, 300 mg/kg of palmitoleic acid, or 300 mg/kg of palmitic acid (C16:0) on a daily basis for 4 weeks.

Results: Palmitoleic acid reduced body weight increase, ameliorated the development of hyperglycemia and hypertriglyceridemia, and improved insulin sensitivity. In addition, hepatic characteristics were significantly affected, as weight of the liver and hepatic triglyceride levels were lower in the palmitoleic acid group when compared to the control (vehicle and palmitic acid groups). Oil red O staining clearly indicated reduced hepatic lipid accumulation in response to palmitoleic acid. Furthermore, palmitoleic acid down-regulated mRNA expressions of proinflammatory adipocytokine genes (TNFα and resistin) in white adipose tissue and lipogenic genes (SREBP-1, FAS, and SCD-1) in liver.

Conclusions: These results suggest that palmitoleic acid improves hyperglycemia and hypertriglyceridemia by increasing insulin sensitivity, in part owing to suppressing proinflammatory gene expressions and improving hepatic lipid metabolism in diabetic mice.

Figures

Figure 1
Figure 1
Effect of palmitoleic acid on plasma glucose concentrations in KK-Ay mice. Animals were orally administered vehicle (control), 300 mg/kg of palmitic acid, or 300 mg/kg palmitoleic acid on a daily basis for 4 weeks. Values are means ± SE, n = 10. *p < 0.05 compared with the control group. C16:0, palmitic acid; C16:1, palmitoleic acid.
Figure 2
Figure 2
Effect of palmitoleic acid on insulin resistance in KK-Ay mice. Animals were orally administered vehicle (control), 300 mg/kg of palmitic acid, or 300 mg/kg palmitoleic acid on a daily basis for 4 weeks. (A) Plasma glucose levels in an insulin tolerance test. The insulin tolerance test was carried out on day 22 of the 4-week experiment. Animals were deprived of food for 5 h before administration of the insulin. Blood samples were collected immediately before the insulin injection (0 min) and 30, 60, and 120 min later. Values are means ± SE, n = 10. p < 0.1 and *p < 0.05 compared with the control group. (B) Plasma insulin levels. Blood samples were collected at the end of 4-week experiment after over-night fasting. Means in a row with superscripts without common letter are different, p < 0.05. C16:0, palmitic acid; C16:1, palmitoleic acid.
Figure 3
Figure 3
Effect of palmitoleic acid on hepatic steatosis in KK-Ay mice. Animals were orally administered vehicle (control), 300 mg/kg of palmitic acid, or 300 mg/kg palmitoleic acid on a daily basis for 4 weeks. Graphs depicting neutral lipid accumulation in liver tissue are shown. (A) Hepatic triglyceride concentration. Values are means ± SE, n = 10. Means in a row with superscripts without common letter are different, p < 0.05. C16:0, palmitic acid; C16:1, palmitoleic acid. (B) Oil red O staining of liver sections from control (I), palmitic acid (II), and palmitoleic acid (III) groups of KK-Aymice. Images are shown at 20× magnification. Scale bar = 100 μm.
Figure 4
Figure 4
Effect of palmitoleic acid on lipogenic gene expression in liver in KK-Ay mice. Animals were orally administered vehicle (control), 300 mg/kg of palmitic acid, or 300 mg/kg palmitoleic acid on a daily basis. (A) Relative mRNA expression levels of SREBP-1; (B) Relative mRNA expression levels of FAS; (C) Relative mRNA expression levels of SCD-1. Each value is the mean ± SE, n = 10. Means in a row with superscripts without common letter are different, p < 0.05. C16:0, palmitic acid; C16:1, palmitoleic acid; SREBP-1, sterol regulatory element binding protein 1; SCD-1, stearoyl-coenzyme A desaturase 1; FAS, fatty acid synthase.
Figure 5
Figure 5
Effect of palmitoleic acid on adipocytokine mRNA levels in adipose tissue in KK-Ay mice. Animals were orally administered vehicle (control), 300 mg/kg of palmitic acid, or 300 mg/kg palmitoleic acid on a daily basis. (A) Relative mRNA expression levels of TNFα; (B) Relative mRNA expression levels of resistin; (C) Relative mRNA expression levels of adiponectin. Each value is the mean ± SE, n = 10. Means in a row with superscripts without common letter are different, p < 0.05. C16:0, palmitic acid; C16:1, palmitoleic acid; TNFα, Tumor necrosis factor alpha.

References

    1. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173–194. doi: 10.2337/diacare.14.3.173.
    1. Misra A, Singhal N, Khurana L. Obesity, the metabolic syndrome, and type 2 diabetes in developing countries: role of dietary fats and oils. J Am Coll Nutr. 2010;29:289S–301S.
    1. Risérus U, Willett WC, Hu FB. Dietary fats and prevention of type 2 diabetes. Prog Lipid Res. 2009;48:44–51. doi: 10.1016/j.plipres.2008.10.002.
    1. Yang B, Kallio HP. Fatty acid composition of lipids in sea buckthorn (Hippophaë rhamnoides L.) berries of different origins. J Agric Food Chem. 2001;49:1939–1947. doi: 10.1021/jf001059s.
    1. Maguire LS, O'Sullivan SM, Galvin K, O'Connor TP, O'Brien NM. Fatty acid profile, tocopherol, squalene and phytosterol content of walnuts, almonds, peanuts, hazelnuts and the macadamia nut. Int J Food Sci Nutr. 2004;5:171–178.
    1. Ozogul Y, Ozogul F, Cicek E, Polat A, Kuley E. Fat content and fatty acid compositions of 34 marine water fish species from the Mediterranean Sea. Int J Food Sci Nutr. 2008;29:1–12.
    1. Morgan NG, Dhayal S. Unsaturated fatty acids as cytoprotective agents in the pancreatic beta-cell. Prostaglandins Leukot Essent Fatty Acids. 2010;82:231–236. doi: 10.1016/j.plefa.2010.02.018.
    1. Morgan NG, Dhayal S, Diakogiannaki E, Welters HJ. Unsaturated fatty acids as cytoprotective agents in the pancreatic beta-cell. Biochem Soc Trans. 2008;36:905–908. doi: 10.1042/BST0360905.
    1. Matthan NR, Dillard A, Lecker JL, Ip B, Lichtenstein AH. Effects of dietary palmitoleic acid on plasma lipoprotein profile and aortic cholesterol accumulation are similar to those of other unsaturated fatty acids in the F1B golden Syrian hamster. J Nutr. 2009;139:215–221.
    1. Griel AE, Cao Y, Bagshaw DD, Cifelli AM, Holub B, Kris-Etherton PM. A macadamia nut-rich diet reduces total and LDL-cholesterol in mildly hypercholesterolemic men and women. J Nutr. 2008;138:761–767.
    1. Garg ML, Blake RJ, Wills RB. Macadamia nut consumption lowers plasma total and LDL cholesterol levels in hypercholesterolemic men. J Nutr. 2003;133:1060–1063.
    1. Cao H, Gerhold K, Mayers JR, Wiest MM, Watkins SM, Hotamisligil GS. Identification of a lipokine, a lipid hormone linking adipose tissue to systemic metabolism. Cell. 2008;134:933–944. doi: 10.1016/j.cell.2008.07.048.
    1. Fujita T, Sugiyama Y, Taketomi S, Sohda T, Kawamatsu Y, Iwatsuka H, Suzuoki Z. Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent. Diabetes. 1983;32:804–810. doi: 10.2337/diabetes.32.9.804.
    1. Folch J, Lees M, Stanley GHS. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 1956;226:497–509.
    1. Fletcher B, Gulanick M, Lamendola C. Risk factors for type 2 diabetes mellitus. J Cardiovasc Nurs. 2002;16:17–23.
    1. Perseghin G, Petersen KF, Rothman DL, Cline GW, Shulman GI. Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest. 1996;97:2859–2865. doi: 10.1172/JCI118742.
    1. Boden G. Effects of free fatty acids (FFA) on glucose metabolism: significance for insulin resistance and type 2 diabetes. Exp Clin Endocrinol Diabetes. 2003;111:121–124.
    1. Dimopoulos N, Watson M, Sakamoto K, Hundal HS. Differential effects of palmitate and palmitoleate on insulin action and glucose utilization in rat L6 skeletal muscle cells. Biochem J. 2006;399:473–481. doi: 10.1042/BJ20060244.
    1. Tsuchiya Y, Hatakeyama H, Emoto N, Wagatsuma F, Matsushita S, Kanzaki M. Palmitate-induced down-regulation of sortilin and impaired GLUT4 trafficking in C2C12 myotubes. J Biol Chem. 2010;285:34371–34381. doi: 10.1074/jbc.M110.128520.
    1. Fasshauer M, Paschke R. Regulation of adipocytokines and insulin resistance. Diabetologia. 2003;46:1594–1603. doi: 10.1007/s00125-003-1228-z.
    1. Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, Capeau J, Feve B. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw. 2006;17:4–12.
    1. Lihn AS, Pedersen SB, Richelsen B. Adiponectin: action, regulation and association to insulin sensitivity. Obes Rev. 2005;6:13–21. doi: 10.1111/j.1467-789X.2005.00159.x.
    1. Hotamisligil GS. Mechanisms of TNF-alpha-induced insulin resistance. Exp Clin Endocrinol Diabetes. 1999;107:119–125. doi: 10.1055/s-0029-1212086.
    1. Barnes KM, Miner JL. Role of resistin in insulin sensitivity in rodents and humans. Curr Protein Rept Sci. 2009;10:96–107. doi: 10.2174/138920309787315239.
    1. Donath MY, Halban PA. Decreased beta-cell mass in diabetes: significance, mechanisms and therapeutic implications. Diabetologia. 2004;47:581–589. doi: 10.1007/s00125-004-1336-4.
    1. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52:102–110. doi: 10.2337/diabetes.52.1.102.
    1. Maedler K, Oberholzer J, Bucher P, Spinas GA, Donath MY. Monounsaturated fatty acids prevent the deleterious effects of palmitate and high glucose on human pancreatic beta-cell turnover and function. Diabetes. 2003;52:726–733. doi: 10.2337/diabetes.52.3.726.
    1. Shimano H. Sterol regulatory element-binding proteins (SREBPs): transcriptional regulators of lipid synthetic genes. Prog Lipid Res. 2001;40:439–452. doi: 10.1016/S0163-7827(01)00010-8.
    1. Lockman KA, Nyirenda MJ. Interrelationships between hepatic fat and insulin resistance in non-alcoholic fatty liver disease. Curr Diabetes Rev. 2010;6:341–347. doi: 10.2174/157339910793360879.
    1. Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol. 2006;7:85–96.
    1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221–1231. doi: 10.1056/NEJMra011775.
    1. Holbrook TL, Barrett-Connor E, Wingard DL. The association of lifetime weight and weight control patterns with diabetes among men and women in an adult community. Int J Obes. 1989;13:723–729.
    1. Aucott LS. Influences of weight loss on long-term diabetes outcomes. Proc Nutr Soc. 2008;67:54–59. doi: 10.1017/S0029665108006022.
    1. Paulson QX, Hong J, Holcomb VB, Nunez NP. Effects of body weight and alcohol consumption on insulin sensitivity. Nutr J. 2010;9:14. doi: 10.1186/1475-2891-9-14.
    1. Walford RL, Mock D, Verdery R, MacCallum T. Caloric restriction in biosphere 2: alterations in physiologic, hematologic, hormonal, and biochemical parameters in humans restricted for a 2-year period. J Gerontol Biol Sci. 2002;57:B211–224. doi: 10.1093/gerona/57.6.B211.
    1. Wang H, Storlien LH, Huang XF. Effects of dietary fat types on body fatness, leptin, and ARC leptin receptor, NPY, and AgRP mRNA expression. Am J Phys Med. 2002;282:E1352–1359.
    1. Hirasawa1 A, Tsumaya K, Awaji T, Katsuma S, Adachi T, Yamada M, Sugimoto Y, Miyazaki S, Tsujimoto G. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med. 2004;11:90–94.
    1. Oh da Y, Talukdar S, Bae EJ, Imamura T, Morinaga H, Fan W, Li P, Lu WJ, Watkins SM, Olefsky JM. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell. 2010;142:687–698. doi: 10.1016/j.cell.2010.07.041.
    1. Feltrin KL, Little TJ, Meyer JH, Horowitz M, Rades T, Wishart J, Feinle-Bisset C. Comparative effects of intraduodenal infusions of lauric and oleic acids on antropyloroduodenal motility, plasma cholecystokinin and peptide YY, appetite, and energy intake in healthy men. Am J Clin Nutr. 2008;87:1181–1187.
    1. Wang Y, Asakawa A, Inui A, Kosai K. Leptin gene therapy in the fight against diabetes. Expert Opin Biol Ther. 2010;10:1405–1414. doi: 10.1517/14712598.2010.512286.
    1. Little TJ, Horowitz M, Feinle-Bisset C. Role of cholecystokinin in appetite control and body weight regulation. Obes Rev. 2005;6:297–306. doi: 10.1111/j.1467-789X.2005.00212.x.
    1. Ahrén B. Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Nat Rev Drug Discov. 2009;8:369–385. doi: 10.1038/nrd2782.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться